The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
450
Occlutech Flex II PFO Closure Device
Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Effective Closure Rate of PFO
Time frame: Twelve Months
Non-Fatal Recurrent Stroke
Time frame: Enrollment to 12 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Cardiovascular Research Center
Phoenix, Arizona, United States
Stanford University Medical Center
Stanford, California, United States
Los Robles Medical Center
Thousand Oaks, California, United States
Colorado Heart and Vascular PC / St. Anthony Hospital
Lakewood, Colorado, United States
South Denver Cardiology Associates
Littleton, Colorado, United States
Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
Rush University Medical Center
Chicago, Illinois, United States
OSF Saint Francis Medical Center
Peoria, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
MaineHealth
Portland, Maine, United States
...and 38 more locations